Literature DB >> 1820978

Expression of cytochrome P-450 mRNAs in steroidogenesis of adrenocortical adenomas from patients with primary aldosteronism.

A Ogo1, M Haji, M Ohashi, H Nawata.   

Abstract

We studied the contents of aldosterone and cortisol (F) and the expression of mRNA of cytochrome P-450 for side-chain cleavage (P-450scc), 17 alpha-hydroxylase (P-450c17), 21-hydroxylase (P-450c21) and 11 beta-hydroxylase (P-450c11) in adrenocortical adenomas from three patients with primary aldosteronism. The aldosterone content was significantly higher in adrenocortical adenomas than in normal adrenal glands, while F content in adenomas was similar to the level in normal adrenal glands. The aldosterone-producing adenomas showed a markedly higher level of P-450c11 mRNA, a slightly but not significantly increased level of P-450c21 mRNA and a significantly decreased level of P-450c17 mRNA, compared with those in normal adrenal glands. The expression of P-450scc mRNA in adenomas was similar to the level in normal adrenal glands. These results suggested that the renin-independent overproduction of aldosterone in adrenocortical adenomas from the patients with primary aldosteronism results from increasing expression of the mRNA for P-450c11 and decreasing expression of the mRNA for P-450c17.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1820978     DOI: 10.1016/0303-7207(91)90254-p

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  2 in total

1.  A dispensable role for P450(scc) in the overproduction of aldosterone in aldosterone-producing adenoma and idiopathic hyperaldosteronism in patients with primary aldosteronism.

Authors:  Yujiang Fang; Lei Zhao; Meifu Zang; Songsen Chen; Feng Yan; Xu Di; Alicia Duren
Journal:  Pathol Oncol Res       Date:  2010-01-12       Impact factor: 3.201

2.  Determination of urinary 18-hydroxycortisol in the diagnosis of primary aldosteronism.

Authors:  I Miyamori; Y Takeda; H Takasaki; Y Itoh; K Iki; R Takeda
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.